19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
08:00 , Jan 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Neuropeptide Y receptor Y2 (NPY2R); peptide tyrosine-tyrosine (PYY) Mouse studies suggest PYY delivered as an...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

LX4211 tablet: Phase I data

Top-line data from a triple-crossover, U.S. Phase I trial in 18 patients showed that 400 mg oral LX4211 plus 100 mg oral Januvia sitagliptin decreased PPG vs. Januvia alone (p=0.012). The combination also increased...
07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

EndoBarrier Gastrointestinal Liner endocrine/metabolic data

Data from 17 obese patients with Type II diabetes showed that EndoBarrier Gastrointestinal Liner significantly reduced mean HbA1c at week 24 by 1.4% from 8.4% at baseline (p<0.01), with an excess mean weight loss of...
08:00 , Feb 7, 2011 |  BioCentury  |  Product Development

Obesity Reset

Even after FDA rejected the advice of its advisory committee and requested a cardiovascular outcomes trial of Orexigen Inc.'s Contrave bupropion/naltrexone to treat obesity, companies with earlier stage programs remain hopeful they will be able...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Clinical News

LX4211 tablet: Phase I data

A Phase I trial in 12 patients showed that 2 doses of 150 mg solid oral LX4211 significantly increased total glucagon-like peptide-1 (GLP-1), active GLP-1 and peptide YY (PYY) from baseline (p=0.001, p=0.032 and...
08:00 , Jan 10, 2011 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biotie Therapies Corp. (HSE:BTH1V) gained €0.18 (36%) to €0.68 on Monday after partner H. Lundbeck A/S (CSE:LUN) said it plans to submit an MAA next half for nalmefene to treat alcohol addiction. Biotie was...
01:37 , Jan 7, 2011 |  BC Extra  |  Clinical News

Lexicon jumps on diabetes data

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) jumped $0.69 (46%) to $2.20 on Thursday after reporting data from a Phase I trial of solid oral LX4211 to treat Type II diabetes. The sodium-glucose cotransporter type 2 ( SGLT2)...